Valuation: Marvel Biosciences Corp.

Market Cap 9.47M 6.79M 6.08M 5.59M 5.07M 645M 9.65M 66.69M 26.77M 339M 25.48M 24.93M 1.07B P/E 2024
-2.91x
P/E 2025 -3.74x
Enterprise Value 11.65M 8.35M 7.48M 6.88M 6.23M 793M 11.87M 82.05M 32.94M 417M 31.34M 30.68M 1.32B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
80.91%
Yield 2024 *
-
Yield 2025 -
10-19 Marvel Biosciences and Marvel Biotechnology Inc Advance MB-204 Toward First-in Human Testing CI
10-08 Marvel Biosciences Corp. and Its Subsidiary Marvel Biotechnology Inc. Reports Preliminary Results From Preclinical Study Of MB-204 In Shank3 Mouse Model CI
10-06 Marvel Biosciences Inks LOI With Clinical Research Organization For Phase 1 MB-204 Trial MT
10-06 Novatech and Marvel Biosciences Corp. Sign Letter of Intent for Phase 1 Trial of Mb-204 CI
09-30 Marvel Biosciences Closes Private Placement MT
09-29 Marvel Biosciences Corp. announced that it has received CAD 1.598145 million in funding CI
08-05 Marvel Biosciences Corp. and Marvel Biotechnology Inc. Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural And Cognitive Deficits In A Mouse Model Of Fragile X CI
07-16 Marvel Biosciences Corp. announced that it expects to receive CAD 3 million in funding CI
06-18 Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026 CI
06-08 Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204 MT
06-08 Marvel Biosciences Corp. Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for Mb-204 CI
04-17 Marvel Biosciences Corp. announced that it has received CAD 0.5 million in funding CI
04-16 Marvel Biosciences Corp. and Marvel Biotechnology Inc Identify Liquid Formulations for Neurodevelopmental Disorders CI
1 week+4.35%
Current month-22.58%
1 month-22.58%
3 months-27.27%
6 months-27.27%
Current year-11.11%
1 week 0.12
Extreme 0.115
0.12
1 month 0.1
Extreme 0.095
0.16
Current year 0.1
Extreme 0.095
0.25
1 year 0.1
Extreme 0.095
0.25
3 years 0.06
Extreme 0.055
0.4
5 years 0.01
Extreme 0.01
0.4
10 years 0.01
Extreme 0.01
0.4
Manager TitleAgeSince
Chief Executive Officer - 14/06/2021
Director of Finance/CFO 37 01/02/2022
President 54 14/06/2021
Director TitleAgeSince
Chairman - -
Director/Board Member 54 14/06/2021
Director/Board Member 57 14/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 A Option

Director

16,667 0.0264%
9/1/26 A Tax

Director

16,667 0.0264%
9/1/26 A Tax

Director

16,667 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.35%-45.45%+71.43% 6.33M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.04%+12.64%+83.62% 56.16B
+0.53%+2.55%+13.90%+104.77% 54.16B
-2.81%-3.95%+22.72%+48.57% 45.33B
-0.33%-3.12%+17.62%+117.27% 42.25B
+0.55%+1.93%+229.73%+928.00% 40.78B
+3.27%+47.40%+110.44%+94.92% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.09%+4.68%+43.04%+154.87% 39.27B
Weighted average by Cap. +0.02%+3.64%+49.57%+162.47%

Financials

2024 2025
Net sales - -
Net income -1.65M -1.18M -1.06M -974K -883K -112M -1.68M -11.62M -4.66M -59.07M -4.44M -4.34M -186M -2.21M -1.58M -1.42M -1.31M -1.18M -150M -2.25M -15.57M -6.25M -79.16M -5.95M -5.82M -250M
Net Debt 1.36M 978K 876K 805K 730K 92.84M 1.39M 9.61M 3.86M 48.84M 3.67M 3.59M 154M 2.18M 1.56M 1.4M 1.29M 1.17M 148M 2.22M 15.36M 6.16M 78.08M 5.87M 5.74M 246M
Projected Income Statement - Annual - Marvel Biosciences Corp.
Logo Marvel Biosciences Corp.
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Employees
-
Date Price Change Volume
30/10/26 CA$0.1200 0.00% 5,000
29/10/26 CA$0.1200 0.00% 5,569
28/10/26 CA$0.1200 0.00% 29,000
27/10/26 CA$0.1200 -4.00% 85,605
26/10/26 CA$0.1250 +8.70% 58,559
  1. Stock Market
  2. Stocks
  3. MRVL Stock